In the context of diabetes, GLP‐1 therapy is widely used in clinical practice, to improve glucose uptake and disposal, and given that muscle loss and the incidence of sarcopenia is accelerated in patients with diabetes (Park et al., 2007), GLP‐1 therapies may also have a role to play in maintaining muscle mass. The gene discussed is GCG; the disease is diabetes mellitus.